advanced-prostate-cancer-care-2026-sapa.md
Source type:
memory· Harvested: 2026-05-04 · Original date: 2026-05-04T09:17:08.502Z Metadata:{"original_path":"advanced-prostate-cancer-care-2026-sapa.md"}
Advanced Prostate Cancer Care 2026 SAPA Deck
Date: 2026-05-04
Deliverable
- Local package folder:
/Users/lunhsiangyuan/Desktop/advanced-prostate-cancer-care-2026-sapa-package - Google Drive path:
gdrive:演講資料/advanced-prostate-cancer-care-2026-sapa-package - Google Drive link: https://drive.google.com/open?id=1lOMjLzWRzFi__-uj_NssIh66HCKQhd5q
Package Contents
advanced-prostate-cancer-care-2026-sapa-light.pptx: final bright SAPA / Apple-style PowerPoint deck, 45 slides.advanced-prostate-cancer-care-2026-summary.docx: resident-facing lecture summary with references.advanced-prostate-cancer-care-2026-summary.md: editable Markdown source for the summary.figures/: trial figure screenshots and remade concept diagrams.previews/contact-sheet-light.png: deck contact sheet preview.README.md: package manifest and notes.
Design And Formatting Notes
- Requested style: bright background, SAPA / Apple-like minimalist style.
- Font direction: Apple-style fonts, using SF Pro Text with PingFang TC fallback for Traditional Chinese.
- Title placement was shifted right to avoid overlap with the template accent.
- Concept diagrams were redrawn as clean image-based figures rather than raw slide clutter.
Clinical Content Notes
- Audience: urology residents, 50-minute lecture on care of advanced prostate cancer.
- Guideline frame: NCCN, EAU, ESMO, ASCO, AUA/SUO updates, with current-source verification during generation.
- Trial figures included: ARANOTE rPFS, ARASENS OS, TALAPRO-2 rPFS and subgroup figure, PSMAfore OS.
- Disease-state teaching flow covers nmCRPC, mHSPC, mCRPC, sequencing, complications, and resident-level clinical decision points.
- AACR 2026 section was expanded into abstract-card teaching slides, including AB#825, #3920, #2429, #10376, #2447, #4488, #2714, #4754, #1888, #4349, #6053, and #1591.
- AACR teaching angle: explain drug-development trends in AR degraders, AR-V7/AR resistance, PTEN/AKT pathway, PSMA/alpha radioligand therapy, target hunting beyond PSMA, serial monitoring, and neuroendocrine transition.
- Recent regulatory note included: April 30, 2026 FDA ODAC favorable vote for capivasertib + abiraterone in PTEN-deficient mHSPC.
- AUA 2026 was future/pending as of 2026-05-04, so the deck used it as a watch list rather than claiming published meeting results.
[← 回 Alfred Brain Hub]